Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Overview | Financials
Company Name Avalo Therapeutics, Inc.
Symbol AVTX
Currency USD
Price 8.81
Market Cap 92,184,316
Dividend Yield 0%
52-week-range 3.95 - 34.46
Industry Biotechnology
Sector Healthcare
CEO Dr. Garry A. Neil M.D.
Website https://www.avalotx.com

An error occurred while fetching data.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as

Related Stocks

Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

IMMX

2.18 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.345 USD

Microbot Medical Inc. logo

Microbot Medical Inc.

MBOT

0.997 USD

Financials

Numbers are in millions USD

Numbers are in millions USD